ArticleEndocrine2022
Fasting plasma glucose in the first trimester is related to gestational diabetes mellitus and adverse pregnancy outcomes.
Article in Endocrine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Gestational diabetes mellitus and adverse pregnancy outcomes: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2022 · on this mapPooled it
- Diagnostic utility of fasting versus non-fasting blood glucose: contextualising testing strategies-a narrative review.Diabetology & metabolic syndrome · 2026Review
- Development and validation of a multidimensional indicator-based risk prediction model for gestational diabetes mellitus: a nested case-control study.BMC endocrine disorders · 2026Article
- Lipid metabolism-based machine learning models for predicting large for gestational age in non-diabetic pregnancies.Frontiers in endocrinology · 2026Article
- Maternal Pre-Pregnancy Glycemic Status and Developmental Outcomes in Korean Children Aged 18-36 Months: A Nationwide Population-Based Cohort Study (2014-2021).Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- Emerging biomarkers for gestational diabetes mellitus and related pediatric outcomes.World journal of clinical pediatrics · 2025Review
- GC vitamin D-binding protein gene functional genetic variants and gestational diabetes mellitus risk and prediction.Scientific reports · 2025Article
- Rapid and high-sensitivity screening of pregnancy complications by profiling circulating placental extracellular vesicles.Science advances · 2025Article
- Universal screening for hyperglycemia in early pregnancy and the risk of adverse pregnancy outcomes.BMC pregnancy and childbirth · 2025Article
- Causal inference and risk prediction of gestational diabetes mellitus based on case-control study and Mendel randomization.Frontiers in nutrition · 2025Article
- Assessment of maternal and neonatal outcomes in pregnant women with and without gestational diabetes mellitus diagnosed at the three trimesters of pregnancy: a cross-sectional study in a hospital in Northeast Mexico.The Pan African medical journal · 2025Article
- Prediction of gestational diabetes mellitus using early-pregnancy data: a secondary analysis from a prospective cohort study in Iran.BMC pregnancy and childbirth · 2024Article
- Prediction of gestational diabetes mellitus by multiple biomarkers at early gestation.BMC pregnancy and childbirth · 2024Article
- Functional genetic variants and susceptibility and prediction of gestational diabetes mellitus.Scientific reports · 2024Article
- Article
- Serum progesterone, glycosylated hemoglobin and insulin levels with the risk of premature rupture of membranes in gestational diabetes mellitus.Clinics (Sao Paulo, Brazil) · 2024Article
- Establishment and evaluation of a risk prediction model for gestational diabetes mellitus.World journal of diabetes · 2023Article
- Article
- Article
- Predictive value of first-trimester GPR120 levels in gestational diabetes mellitus.Frontiers in endocrinology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo investigate and identify first-trimester fasting plasma glucose (FPG) is related to gestational diabetes mellitus (GDM) and other adverse pregnancy outcomes in Shenzhen population.
methodsWe used data of 48,444 pregnant women that had been retrospectively collected between 2017 and 2019. Logistic regression analysis was used to evaluated the associations between first-trimester FPG and GDM and adverse pregnancy outcomes, and used to construct a nomogram model for predicting the risk of GDM. The performance of the nomogram was evaluated by using ROC and calibration curves. Decision curve analysis (DCA) was used to determine the clinical usefulness of the first-trimester FPG by quantifying the net benefits at different threshold probabilities.
resultsThe mean first-trimester FPG was 4.62 ± 0.42 mmol/L. A total of 6998 (14.4%) pregnancies developed GDM.489(1.01%) pregnancies developed polyhydramnios, the prevalence rates of gestational hypertensive disorder (GHD), cesarean section, primary cesarean section, preterm delivery before 37 weeks (PD) and dystocia was 1130 (2.33%), 20,426 (42.16%), 7237 (14.94%), 2386 (4.93%), and 1865 (3.85%), respectively. 4233 (8.74%) of the newborns were LGA, and the number of macrosomia was 2272 (4.69%), LBW was 1701 (3.51%) and 5084 (10.49%) newborns had admission to the ICU, which all showed significances between GDM and non-GDM groups (all P < 0.05). The univariate analysis showed that first-trimester FPG was strongly associated with risks of outcomes including GDM, cesarean section, macrosomia, GHD, primary cesarean section, and LGA (all OR > 1, all P < 0.05), furthermore, the risks of GDM, primary cesarean section, and LGA was increasing with first-trimester FPG as early as it was at 4.19-4.63 mmol/L. The multivariable analysis showed that the risks of GDM (ORs for FPG 4.19-4.63, 4.63-5.11 and 5.11-7.0 mmol/L were 1.137, 1.592, and 4.031, respectively, all P < 0.05) increased as early as first-trimester FPG was at 4.19-4.63 mmol/L, and first-trimester FPG which was also associated with the risks of cesarean section, macrosomia and LGA (OR for FPG 5.11-7.0 mmol/L of cesarean section: 1.128; OR for FPG 5.11-7.0 mmol/L of macrosomia: 1.561; OR for FPG 4.63-5.11 and 5.11-7.0 mmol/L of LGA: 1.149 and 1.426, respectively, all P < 0.05) and with its increasing, the risks of LGA increased. Furthermore, the nomogram had a C-indices 0.771(95% CI: 0.763~0.779) and 0.770(95% CI:0.758~0.781) in training and testing validation respectively, which showed an acceptable consistency between the observed, validation and nomogram-predicted probabilities, the DAC curve analysis indicated that the nomogram had important clinical application value for GDM risk prediction.
conclusionsFPG in the first trimester was an independent risk factor for GDM which can be used as a screening test for identifying pregnancies at risk of GDM and adverse pregnancy outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.